{"id":4454,"date":"2026-11-20T09:00:00","date_gmt":"2026-11-20T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4454"},"modified":"2026-11-21T09:11:44","modified_gmt":"2026-11-21T13:11:44","slug":"fda-extends-tinlarebant-review-to-may-2027","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4454","title":{"rendered":"FDA Extends Tinlarebant Review to May 2027"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_Belite_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4477\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_Belite_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_Belite_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_Belite_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_Belite_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Belite Bio<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA review extension (PDUFA date moved from Feb 12 to May 12, 2027)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Oral small molecule<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Tinlarebant<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Retinol-binding protein 4<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Stargardt disease type 1<\/p>\n<h4>Summary<\/h4>\n<p>Belite Bio disclosed November 20 that FDA extended the review goal for tinlarebant in Stargardt disease type 1 by three months, from February 12 to May 12, 2027. The extension changes the regulatory clock; the agency did not disclose a final benefit-risk judgment.<\/p>\n<p>The company and accompanying Form 6-K say FDA needs additional time to review information submitted during the NDA process. Belite states April 12 is the proposed-label date if no major deficiencies remain, which is a conditional process milestone rather than approval guidance. Detailed reasons for the review extension were not disclosed.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> an extended review could reflect ordinary evaluation of a major amendment or new information. Counterpoint: the undisclosed information may still reveal substantive concerns.<\/p>\n<p><strong>Interpretation B:<\/strong> the shift could signal greater scrutiny of efficacy, safety or CMC. Counterpoint: the company and filing do not identify which area prompted the extension, so causal attribution is not justified. The pivotal DRAGON trial was small and the disease evolves slowly; clinically meaningful structural and visual-function durability remain central to evaluation.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Tinlarebant is an oral retinol-binding protein 4 modulator intended to reduce retinal vitamin-A delivery and toxic bisretinoid formation in autosomal-recessive ABCA4-linked Stargardt disease.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified facts: company release, SEC 6-K and new date.<\/li>\n<li>Company claim: Phase 3 success announced earlier.<\/li>\n<li>Missing: FDA correspondence, exact amendment category, review discipline and label language.<\/li>\n<li>Upgrade: accepted label and approval.<\/li>\n<li>Downgrade: complete response or further data demand.<\/li>\n<li>Falsifier for a substantive-deficiency thesis: routine approval on the revised clock.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Timing uncertainty has increased, while the direction of the benefit-risk assessment remains unknown.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: neutral. Confidence in Facts: High. Confidence in Interpretation: Low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Belite Bio disclosed November 20 that FDA extended the review goal for tinlarebant in Stargardt disease type 1 by three months, from February 12 to May 12, 2027. The extension changes the regulatory clock;&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4477,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1559,1561,1560],"class_list":["post-4454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-belite-bio","tag-stargardt-disease","tag-tinlarebant"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4454"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4454\/revisions"}],"predecessor-version":[{"id":4478,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4454\/revisions\/4478"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4477"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}